Tufts Medical Center
tuftsmedicalcenter.orgTotal trials
195
Active
31
Phase 3
15
Total enrollment
102,015
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 11 of 11 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Letermovir | — | — | — | — | — | 2 | |
| Vitamin D | — | — | — | — | — | 1 | |
| veverimer daily | — | — | — | — | — | 1 | |
| veverimer every other day | — | — | — | — | — | 1 | |
| Adalimumab | — | — | — | — | 2 | ||
| Tocilizumab | — | — | — | — | — | 2 | |
| Vasopressor | — | — | — | — | — | 1 | |
| Inotrope | — | — | — | — | — | 1 | |
| Etanercept | — | — | — | — | — | 1 | |
| Upadacitinib | — | — | — | — | — | 1 | |
| Indocyanine green | — | — | — | — | — | 1 |
Next readouts
- 2025-12
- 2025-12-15
- 2026-01-01
- 2027-12-15
- 2028-03-01
- 2030-03
Top conditions
- Heart Failure7
- Psoriasis6
- Obesity6
- Chronic Kidney Disease5
- Heart Diseases5
- Knee Osteoarthritis4
- Cardiovascular Diseases4
- Metabolic Syndrome4
Frequently asked questions about Tufts Medical Center
- How many clinical trials does Tufts Medical Center have on ClinicalTrials.gov?
- Tufts Medical Center is listed as the lead sponsor on 195 clinical trials in ClinicalTrials.gov, 31 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Tufts Medical Center's trials are in Phase 3?
- 15 of Tufts Medical Center's trials are in Phase 3, spread across 11 active drug programs.
- What therapeutic areas does Tufts Medical Center focus on?
- Tufts Medical Center's most-studied conditions on ClinicalTrials.gov are Heart Failure, Psoriasis, Obesity, Chronic Kidney Disease, Heart Diseases.
- When are Tufts Medical Center's next clinical trial readouts?
- Tufts Medical Center has 6 upcoming primary-completion readouts tracked here; the soonest is “SLN Mapping and ICG Dye for Vulvar Cancer”, expected around 2025-12.